INSIGHTS

Introduction India’s pharmaceutical industry has always told two very different stories. On one side, it’s a global success, respected for its ability to manufacture and supply affordable, life-saving medicines to countries around the world. On the other, there’s a much less flattering reality: the persistent and dangerous spread of counterfeit drugs. These aren’t minor fakes. They’re health hazards that not only put patients at risk but also chip away at the trust the entire

Rare diseases pose some of the gravest challenges in healthcare. Though uncommon individually, they collectively affect millions of people worldwide. Often these diseases require specialized, lifelong treatments that come with exorbitant price tags. In India, patients suffering from conditions such as spinal muscular atrophy (SMA), haemophilia, thalassemia, and others face tremendous hurdles obtaining affordable medicines. This has placed compulsory licensing, a legal provisi

INTRODUCTION AstraZeneca's anti-diabetic medication dapagliflozin which has been sold as Forxiga/Farxiga has been the subject of...

The High Court of Delhi has passed an interim order wherein the Justices have made it clear that the appellant (Glenmark) may use any...